Terms: = Breast cancer AND NFE2L2, ENSG00000116044, 4780, Q16236, NRF2 AND Treatment
189 results:
1. Ononin triggers ferroptosis-mediated disruption in the triple negative breast cancer both in vitro and in vivo.
Gong G; Wan Y; Liu Y; Zhang Z; Zheng Y
Int Immunopharmacol; 2024 May; 132():111959. PubMed ID: 38554442
[TBL] [Abstract] [Full Text] [Related]
2. SBFI26 induces triple-negative breast cancer cells ferroptosis via lipid peroxidation.
He G; Zhang Y; Feng Y; Chen T; Liu M; Zeng Y; Yin X; Qu S; Huang L; Ke Y; Liang L; Yan J; Liu W
J Cell Mol Med; 2024 Apr; 28(7):e18212. PubMed ID: 38516826
[TBL] [Abstract] [Full Text] [Related]
3. Peiminine triggers ferroptosis to inhibit breast cancer growth through triggering nrf2 signaling.
Yi N; Wang L; Jiang Z; Xu G; Li L; Zhang Y; Tan Y
Tissue Cell; 2024 Apr; 87():102323. PubMed ID: 38412577
[TBL] [Abstract] [Full Text] [Related]
4. A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Shatsky RA; Batra-Sharma H; Helsten T; Schwab RB; Pittman EI; Pu M; Weihe E; Ghia EM; Rassenti LZ; Molinolo A; Cabrera B; Breitmeyer JB; Widhopf GF; Messer K; Jamieson C; Kipps TJ; Parker BA
Breast Cancer Res; 2024 Feb; 26(1):32. PubMed ID: 38408999
[TBL] [Abstract] [Full Text] [Related]
5. Paris saponin VII promotes ferroptosis to inhibit breast cancer via nrf2/GPX4 axis.
Yan C; Xuan F
Biochem Biophys Res Commun; 2024 Feb; 697():149524. PubMed ID: 38252991
[TBL] [Abstract] [Full Text] [Related]
6. Interplay of oxidative stress, cellular communication and signaling pathways in cancer.
Iqbal MJ; Kabeer A; Abbas Z; Siddiqui HA; Calina D; Sharifi-Rad J; Cho WC
Cell Commun Signal; 2024 Jan; 22(1):7. PubMed ID: 38167159
[TBL] [Abstract] [Full Text] [Related]
7. Danggui Buxue Tang improves therapeutic efficacy of doxorubicin in triple negative breast cancer via ferroptosis.
Gong G; Ganesan K; Liu Y; Huang Y; Luo Y; Wang X; Zhang Z; Zheng Y
J Ethnopharmacol; 2024 Apr; 323():117655. PubMed ID: 38158099
[TBL] [Abstract] [Full Text] [Related]
8. Wogonin Diminishes Radioresistance of breast cancer via Inhibition of the nrf2/HIF-1[Formula: see text] Pathway.
Wang T; Wang P; Wang S; Ma Y; Zhao Z; Long F
Am J Chin Med; 2023; 51(8):2243-2262. PubMed ID: 37903716
[TBL] [Abstract] [Full Text] [Related]
9. FOXA2 Suppression by TRIM36 Exerts Anti-Tumor Role in Colorectal cancer Via Inducing nrf2/GPX4-Regulated Ferroptosis.
Liu X; Yan C; Chang C; Meng F; Shen W; Wang S; Zhang Y
Adv Sci (Weinh); 2023 Dec; 10(35):e2304521. PubMed ID: 37875418
[TBL] [Abstract] [Full Text] [Related]
10. Combinatorial Implications of nrf2 Inhibitors with FN3K Inhibitor:
Beeraka NM; Zhang J; Zhao D; Liu J; A U C; Vikram Pr H; Shivaprakash P; Bannimath N; Manogaran P; Sinelnikov MY; Bannimath G; Fan R
Curr Pharm Des; 2023; 29(30):2408-2425. PubMed ID: 37861038
[TBL] [Abstract] [Full Text] [Related]
11. Ochratoxin A promotes chronic enteritis and early colorectal cancer progression by targeting Rinck signaling.
Liu X; Yan C; Chang C; Meng F; Shen W; Wang S; Zhang Y
Phytomedicine; 2024 Jan; 122():155095. PubMed ID: 37844381
[TBL] [Abstract] [Full Text] [Related]
12. The Therapeutic Effects of MUC1-C shRNA@Fe
Li Z; Guo T; Zhao S; Lin M
Int J Nanomedicine; 2023; 18():5651-5670. PubMed ID: 37822991
[TBL] [Abstract] [Full Text] [Related]
13. The novel β-TrCP protein isoform hidden in circular RNA confers trastuzumab resistance in HER2-positive breast cancer.
Wang S; Wang Y; Li Q; Li X; Feng X; Zeng K
Redox Biol; 2023 Nov; 67():102896. PubMed ID: 37783059
[TBL] [Abstract] [Full Text] [Related]
14. New insights into the cytotoxic effects of Thymus vulgaris essential oil on the human triple-negative breast cancer cell line MDA-MB-231.
Benedetti S; Nasoni MG; Luchetti F; Palma F
Toxicol In Vitro; 2023 Dec; 93():105705. PubMed ID: 37775061
[TBL] [Abstract] [Full Text] [Related]
15. TMED2 Induces Cisplatin Resistance in breast cancer via Targeting the KEAP1-nrf2 Pathway.
Liang C; Zhang HY; Wang YQ; Yang LA; Du YS; Luo Y; Zhang TC; Xu Y
Curr Med Sci; 2023 Oct; 43(5):1023-1032. PubMed ID: 37615927
[TBL] [Abstract] [Full Text] [Related]
16. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
17. A Dual Stimuli-Responsive Nanoplatform Loaded Pt
Fang K; Sun Y; Yang J; Hu X; Chen M; Li R; Yang X; Fan T; Wu J; Tong X; Dong C; Shi S
Adv Healthc Mater; 2023 Nov; 12(28):e2301328. PubMed ID: 37392128
[TBL] [Abstract] [Full Text] [Related]
18. PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis.
Wang Z; Li R; Hou N; Zhang J; Wang T; Fan P; Ji C; Zhang B; Liu L; Wang Y; Kong J; Yao Q; Duan J; Zhao G; Ling R; Zhang J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37380368
[TBL] [Abstract] [Full Text] [Related]
19. Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Wang C; Dai S; Zhao X; Zhang Y; Gong L; Fu K; Ma C; Peng C; Li Y
Biomed Pharmacother; 2023 Jul; 163():114882. PubMed ID: 37196541
[TBL] [Abstract] [Full Text] [Related]
20. A copper complex that combats triple negative breast cancer by restraining angiogenesis.
Zheng H; Hu C; Quan Y; Ye X; Shi X; Guo Z; Wang X
Dalton Trans; 2023 Jun; 52(22):7626-7634. PubMed ID: 37195167
[TBL] [Abstract] [Full Text] [Related]
[Next]
